Curator's Take
AI Commentary
This article flags a critical choke point: without a robust domestic supply chain for specialized lasers, cryogenic systems and low‑loss photonic components, the United States risks turning its quantum research breakthroughs into commercial dead ends. It echoes recent warnings from industry leaders that Europe’s “Quantum Flagship” and China’s state‑backed chip programs are already securing manufacturing capacity, putting U.S. firms at a competitive disadvantage. By urging targeted federal investment in component fabrication and workforce development, the analysts highlight a policy lever that could accelerate the transition from laboratory prototypes to market‑ready quantum processors.
— Mark Eatherly
Summary
Insider Brief U.S. quantum ambitions could outpace the supply chains needed to turn laboratory advances into a commercial industry, four policy analysts warn. In a policy piece published by the Foundation for American Innovation, Joshua Levine, Prineha Narang, Jacqueline Tame and Alexandra Seymour Gabel, write that Washington must invest in the components and manufacturing capacity […]